In addition, the combination of the anti-PD-L1 neutralizing antibody Atezolizumab with the CysLT1R antagonist Mo demonstrated a combinatorial effect in preclinical models of CC, emphasizing the power of combination therapy to promote the success of immunotherapy in CRC. The gene discussed is CYSLTR1; the disease is colorectal carcinoma.